CN Patent

CN119630395A — 用于治疗特发性肺纤维化的组合物和方法

Assigned to Novomix Technology Co ltd · Expires 2025-03-14 · 1y expired

What this patent protects

描述了使用治疗有效量的曲尼司特和吡非尼酮的组合，或者治疗有效量的曲尼司特和尼达尼布的组合治疗特发性肺纤维化(IPF)。曲尼司特可作为吡非尼酮或尼达尼布治疗IPF的辅助治疗药物。曲尼司特和吡非尼酮的组合以及曲尼司特和尼达尼布的组合也可以协同有效地治疗IPF。还描述了用于治疗特发性肺纤维化(IPF)的方法和药物组合物。

USPTO Abstract

描述了使用治疗有效量的曲尼司特和吡非尼酮的组合，或者治疗有效量的曲尼司特和尼达尼布的组合治疗特发性肺纤维化(IPF)。曲尼司特可作为吡非尼酮或尼达尼布治疗IPF的辅助治疗药物。曲尼司特和吡非尼酮的组合以及曲尼司特和尼达尼布的组合也可以协同有效地治疗IPF。还描述了用于治疗特发性肺纤维化(IPF)的方法和药物组合物。

Drugs covered by this patent

Patent Metadata

Patent number: CN119630395A
Jurisdiction: CN
Classification: —
Expires: 2025-03-14
Drug substance claim: No
Drug product claim: No
Assignee: Novomix Technology Co ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.